Crocs managed a 3.5% bounce on July 31st, yet the week still ended 5% lower — and beneath that recovery, short positioning has been drifting higher for a month while the borrow market remains notably loose.
The positioning story is one of cautious accumulation rather than aggressive attack. Short interest has climbed to roughly 8.9% of the free float, up about 4% over the past month and building steadily since early July when it was running above 5.1 million shares. The direction of travel is clear — bears have been adding — but the borrow market tells a different story. Availability has actually loosened sharply, with nearly 10 shares available to borrow for every one already shorted, a level well above the tightest reading of the past year. Cost to borrow has barely moved, sitting below 0.5%, leaving short sellers under no squeeze pressure whatsoever. Options carry a similar sense of moderate caution rather than fear: the put/call ratio is running at 0.89, almost exactly its 20-day average, with a z-score of near zero. After the 52-week high of 1.11 and low of 0.54, the current reading belongs firmly in the middle — no real directional bet from the options market.
The Street split more sharply this week around the earnings result. The broad picture is one of bulls still holding targets well above the current price, while the sideline crowd has moved up its levels after better-than-feared numbers. B of A raised its target to $160 and held its Buy, and two weeks ago Piper Sandler upgraded to Overweight with a $150 target — those voices see 17%-24% upside from $128. UBS and Barclays moved in the opposite spirit: both raised targets after the print but stopped short of anything bullish, UBS landing at $120 and Barclays at $118, both below the current price. That gap says something — the stock has outrun what the neutral camp is willing to pay for. The consensus mean target is $135.75, implying only around 6% upside. Valuation is undemanding on its face — a P/E of 8.6x and EV/EBITDA near 7.7x — but the forward earnings momentum factor scores near the bottom of the universe, with the 12-month forward EPS growth rank in just the 11th percentile. The ORTEX short score has been hovering in the low-50s all week, indicating a broadly neutral short-side setup rather than an extreme.
The earnings reaction itself warrants attention. The July 30th print produced a -4.1% next-day move, which lines up with the pattern of modest post-earnings declines. With no next event flagged in the calendar, the stock is now in a period where price action will be driven by broader consumer discretionary sentiment and any news on the Hey Dude turnaround. Peers had a rough week — VFC fell nearly 16% and BIRK slid 4.7%, while COLM dropped 4.7%. CROX's 5% weekly decline was bad, but not the worst in the peer group.
CEO Andrew Rees sold just over $3.8 million in shares across three tranches in early June at prices between $117 and $119 — slightly below current levels. That selling registered a modest significance score, and the 90-day net is a positive $6.5 million in value terms due to option exercise mechanics, but the directional signal from the CEO is worth keeping in view as the stock climbs back toward $130. The next test is whether CROX can hold its gains in a sector where most names are under pressure — and whether the gradual rebuilding of short interest resumes once the post-earnings relief fades.
See the live data behind this article on ORTEX.
Open CROX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
